[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334780-105":59,"doc-detail-334780-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","discovery-of-wrn-inhibitor-hro761-with-synthetic-lethality-in-msi-cancers","Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers","","Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in microsatellite instability (MSI) cancer cells through multiple genetic screens. Despite progress with immune checkpoint inhibitors, effective therapies for MSI cancers remain an unmet need. The study reports structural, biochemical, cellular and pharmacological characterization of the clinical-stage WRN helicase inhibitor HRO761 and shows it as a potent, selective, allosteric binder that locks WRN in an inactive conformation. HRO761 induces DNA damage and selectively inhibits MSI tumor cell growth, drives WRN degradation in MSI but not microsatellite-stable cells, and suppresses tumor growth in oral in vivo models, supporting WRN as a therapeutic target and motivating ongoing clinical evaluation (NCT05838768).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-wrn-inhibitor-hro761-with-synthetic-lethality-in-msi-cancers/334780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-wrn-inhibitor-hro761-with-synthetic-lethality-in-msi-cancers/334780.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What makes MSI cancers vulnerable to targeting WRN?","Question",{"text":113,"@type":114},"WRN was identified as a synthetic lethal target in MSI cells in multiple genetic screens. WRN suppression leads to DNA damage and anti-proliferative effects in MSI models while sparing cells with intact MMR pathways.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does HRO761 inhibit WRN?",{"text":118,"@type":114},"HRO761 is described as a potent, selective, allosteric WRN inhibitor. It binds at the interface of the D1 and D2 helicase domains, locking WRN into an inactive conformation.",{"name":120,"@type":111,"acceptedAnswer":121},"What effects does HRO761 have on MSI cells in terms of growth and DNA damage?",{"text":122,"@type":114},"Pharmacological inhibition by HRO761 recapitulates WRN genetic suppression, causing DNA damage and inhibiting tumor cell growth selectively in MSI cells. The inhibition operates in a p53-independent manner.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},334780,1790231681,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \n\n| Discovery ofWRN inhibitor HRO761 with synthetic lethalityin MSI cancers |  |  |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41586-024-07350-y](https://doi.org/10.1038/s41586-024-07350-y)\u003Cbr>Received: 26 July 2023 Accepted: 26 March 2024 Published online: 24 April 2024 Open access\u003Cbr> Check for updates | Stephane Ferretti1,5, Jacques Hamon1,5, Ruben de Kanter1,5, Clemens Scheufler1,5,\u003Cbr>Rita Andraos-Rey1, Stephanie Barbe1, Elisabeth Bechter1, Jutta Blank1, Vincent Bordas1, Ernesta Dammassa1, Andrea Decker1, Noemi Di Nanni1, Marion Dourdoigne1, Elena Gavioli1,2, Marc Hattenberger1, Alisa Heuser1, Christelle Hemmerlin1, Jürgen Hinrichs1, Grainne Kerr1, Laurent Laborde1, Isabel Jaco1, Eloísa Jiménez Núñez1,4, Hans-Joerg Martus1, Cornelia Quadt1, Markus Reschke1, Vincent Romanet1, Fanny Schaeffer1, Joseph Schoepfer1, Maxime Schrapp1, Ross Strang1, Hans Voshol1, Markus Wartmann1, Sarah Welly1, Frédéric Zécri3,\u003Cbr>Francesco Hofmann1,4, Henrik Möbitz1 ✉ & Marta Cortés-Cros1 ✉\u003Cbr>The Werner syndrome RecQ helicaseWRN was identified asa synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens1–6. Despite advancesin treatment with immune checkpoint inhibitors7–10, there isan unmet need in the treatment of MSI cancers11–14. Here we report the structural, biochemical, cellular and pharmacological characterization of the clinical-stage WRNhelicase inhibitor HRO761, which was identified through an innovative hit-finding and\u003Cbr>lead-optimization strategy. HRO761 is a potent, selective, allosteric WRN inhibitor that binds atthe interface oftheD1 and D2 helicase domains, locking WRNinan inactive conformation. Pharmacological inhibition by HRO761 recapitulated the phenotype observed by WRN genetic suppression, leading to DNA damage and inhibition of tumour cell growth selectively in MSI cells in ap53-independent manner. Moreover, HRO761 led toWRN degradation in MSI cells but not in microsatellite-stable cells. Oral treatment with HRO761 resulted indose-dependent in vivo DNA damage induction and tumour growth inhibition in MSI cell-and patient-derived xenograft models. These findings represent preclinical pharmacological validation ofWRNasa therapeutic target in MSI cancers. A clinical trial with HRO761 (NCT05838768) is ongoing to assess the safety, tolerability and preliminary anti-tumour activity inpatients with MSI colorectal cancer and other MSI solid tumours. |  |\n| Loss of DNA mismatch repair (MMR) by either germline or somatic |  | response rate to immune checkpoint inhibitors7–10, a substantial frac- |\n| mutations and epigenetic alterations occurs in 10–30% of colorec- |  | tion of patients with MSI colon cancers does not benefit from current |\n| tal, endometrial, ovarian, gastric and other cancer types15,16. Cancers |  | treatment regimens11–14. |\n| that are MMR deficient have a high mutational burden and frequent |  | WRN is a multifunctional enzyme with both helicase and exonu- |\n| insertion and/or deletion events in repetitive DNA tracts—a pheno- |  | clease activities and has roles in various cellular processes that are |\n| type known as MSI17. Several large-scale functional genomics screens, |  | crucial for the maintenance of genome stability, including DNA rep- |\n| including project DRIVE with 390 cell lines from the Cancer Cell Line |  | lication, transcription, DNA repair and telomere maintenance19–22. |\n| Encyclopedia, have identified WRN as a synthetic lethal target in MSI |  | Dissection ofthe helicase and exonuclease enzymatic activities of |\n| cells1–6 (Extended Data Fig. 1a). Genetic depletion ofWRN was shown |  | WRN using loss-of-function mutations showed that WRN dependency |\n| to lead to DNA damage, anti-proliferative effects, mitotic defects with |  | in vitro and in vivo in MSI cells is linked only to its helicase function |\n| cell cycle arrest, chromosome shattering and apoptosis in MSI cancer |  | (Extended Data Fig. 1b–e). Reintroduction ofWRN WTcDNA","cbCailbH9154vCT2","https://ap.wps.com/l/cbCailbH9154vCT2","pdf",16709618,33,"English","# Background and therapeutic need\n## MSI cancers and synthetic lethal vulnerabilities\n# HRO761 discovery and mechanism\n## Allosteric inhibition and structural targeting\n# Cellular and pharmacological effects\n## DNA damage, growth inhibition, and WRN degradation\n# In vivo validation and clinical outlook\n## Oral dosing results and ongoing trial","[{\"question\":\"What makes MSI cancers vulnerable to targeting WRN?\",\"answer\":\"WRN was identified as a synthetic lethal target in MSI cells in multiple genetic screens. WRN suppression leads to DNA damage and anti-proliferative effects in MSI models while sparing cells with intact MMR pathways.\"},{\"question\":\"How does HRO761 inhibit WRN?\",\"answer\":\"HRO761 is described as a potent, selective, allosteric WRN inhibitor. It binds at the interface of the D1 and D2 helicase domains, locking WRN into an inactive conformation.\"},{\"question\":\"What effects does HRO761 have on MSI cells in terms of growth and DNA damage?\",\"answer\":\"Pharmacological inhibition by HRO761 recapitulates WRN genetic suppression, causing DNA damage and inhibiting tumor cell growth selectively in MSI cells. The inhibition operates in a p53-independent manner.\"}]","Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers | PDF",1790008361,83]